Wells Fargo initiated coverage of PTC Therapeutics with an Overweight rating and $37 price target. Shares currently reflect a worst-case outcome for all pipeline/commercial assets, but the stock can rebound following clarity on Translarna’s revenue trajectory and upcoming clinical updates, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PTCT:
- PTC Therapeutics provides regulatory update for Translarna in Europe, the U.S.
- Biotech Alert: Searches spiking for these stocks today
- Roblox upgraded, Bristol Myers downgraded: Wall Street’s top analyst calls
- PTC Therapeutics price target lowered to $23 from $26 at RBC Capital
- PTC Therapeutics price target lowered to $51 from $73 at Cantor Fitzgerald